Fundamental Analysis of VIRPAX PHARMACEUTICALS INC(NASDAQ:VRPX) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to VRPX. VRPX was compared to 193 industry peers in the Pharmaceuticals industry. VRPX has a bad profitability rating. Also its financial health evaluation is rather negative. VRPX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

VRPX had negative earnings in the past year.

In the past year VRPX has reported a negative cash flow from operations.

In the past 5 years VRPX always reported negative net income.

VRPX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of VRPX (-4352.58%) is worse than 99.48% of its industry peers.

		Industry Rank	Sector Rank
ROA	-4352.58%
ROE	N/A
ROIC	N/A

ROA(3y)-99.43%

ROA(5y)-1653.33%

ROE(3y)-316.05%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRPX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for VRPX remains at a similar level compared to 1 year ago.

VRPX has more shares outstanding than it did 5 years ago.

There is no outstanding debt for VRPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -466.48, we must say that VRPX is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of VRPX (-466.48) is worse than 97.38% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-466.48

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

VRPX has a Current Ratio of 0.13. This is a bad value and indicates that VRPX is not financially healthy enough and could expect problems in meeting its short term obligations.

VRPX has a worse Current ratio (0.13) than 99.48% of its industry peers.

VRPX has a Quick Ratio of 0.13. This is a bad value and indicates that VRPX is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of VRPX (0.13) is worse than 99.48% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.13
Quick Ratio	0.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.11% over the past year.

EPS 1Y (TTM)24.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%91.57%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

VRPX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.54% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y64.13%

EPS Next 2Y37.92%

EPS Next 3Y24.54%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VRPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRPX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as VRPX's earnings are expected to grow with 24.54% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.92%

EPS Next 3Y24.54%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for VRPX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIRPAX PHARMACEUTICALS INC

NASDAQ:VRPX (12/20/2024, 7:45:11 PM)

After market: 0.3538 +0.02 (+7.21%)

0.33

+0.01 (+4.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-14 2024-11-14/amc

Earnings (Next)N/A N/A

Inst Owners0.5%

Inst Owner Change531.51%

Ins Owners0.58%

Ins Owner Change0%

Market Cap2.67M

Analysts43.33

Price Target3.06 (827.27%)

Short Float %4.96%

Short Ratio0.09

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)4.9%

Min EPS beat(2)-12.14%

Max EPS beat(2)21.93%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)75.68%

EPS NY rev (1m)0%

EPS NY rev (3m)12.23%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-8.83

EYN/A

EPS(NY)-0.92

Fwd EYN/A

FCF(TTM)-2.08

FCFYN/A

OCF(TTM)-2.08

OCFYN/A

SpS0

BVpS-0.25

TBVpS-0.25

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-4352.58%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-99.43%

ROA(5y)-1653.33%

ROE(3y)-316.05%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.13
Quick Ratio	0.13
Altman-Z	-466.48

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)24.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%91.57%

EPS Next Y64.13%

EPS Next 2Y37.92%

EPS Next 3Y24.54%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y5.23%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y20.51%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y20.51%

OCF growth 3YN/A

OCF growth 5YN/A

VIRPAX PHARMACEUTICALS INC (VRPX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens